Previous 10 | Next 10 |
home / stock / pfe / pfe articles
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading lower by 5.6% to $93.10 Wednesday afternoon. Shares of several COVID vaccine stocks are trading...
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sh...
Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDA...
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and long-term business goals. The compan...
Pfizer Inc (NYSE: PFE) agreed to donate the rights of royalties from sales of cancer drug Bavencio (avelumab) to the American Associ...
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY) announced an exclusive license and collaboration agreement for Sy...
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy o...
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (prima...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 06:15:00 ET If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment for a home and college tuition for kids). The simplest, and arguably bes...
2024-07-25 05:05:00 ET Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this therapeutic area. That's a surprising finding: Pfizer does not ha...
2024-07-24 10:13:00 ET If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are unsure about how strong its long-term prospects are, which ...